3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma
2
Hematologic Neoplasms
2
Subcutaneous panniculitis-like T-cell lymphoma
1
Sezary Syndrome
1
Recurrence
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Infectious Mononucleosis
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Rituximab
16
Cyclophosphamide
12
fludarabine phosphate
8
Peripheral Blood Stem Cell Transplantation
7
Vincristine
5
Radiotherapy
5
Prednisone
5
Lenalidomide
5
Etoposide
5
Doxorubicin
5
Cytarabine
5
Bendamustine Hydrochloride
5
fludarabine
4
Whole-Body Irradiation
4
Filgrastim
4
tazemetostat
3
Mycophenolic Acid
3
Melphalan
3
Carmustine
3
umbralisib
2
ublituximab
2
sargramostim
2
parsaclisib
2
ofatumumab
2
ibritumomab tiuxetan
2
duvelisib
2
Tacrolimus
2
Pentostatin
2
Pentetic Acid
2
Methotrexate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma, Follicular
×
Brentuximab Vedotin
×
Clear all
NCT02623920
2017-05-19
S-BR
University of Arizona
Phase 2
Withdrawn